Replies to post #160939 on Biotech Values

[caravon]

BTH,

I can be reached at
[e-mail]

caravon

PS
It is of interest that Tiva behaves in NSCLC c-MET low pts similar to Avastin in breast cancers, i.e., a very solid PFS improvement and no OS benefits. I intend to raise this issue with ARQL's CMO.